Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 5/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.34 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.34 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL185180 | 0.82 | LRRK2 (0.37) | LRRK2DHODHMAOBKCNQ3KCNQ2 | |
| SCHEMBL186635 | 0.81 | LRRK2 (0.42) | LRRK2MAOBCHEK1JAK2JAK1 | |
| SCHEMBL2809625 | 0.80 | LRRK2 (0.36) | LRRK2DHODHMAOBAR | |
| Cyclopropane SCHEMBL185943 | 0.78 | AURKA (0.39) | DHODH | |
| SCHEMBL2806859 | 0.78 | BDKRB1 (0.40) | LRRK2CHEK1ARVNN1 | |
| SCHEMBL200796 | 0.76 | FAAH (0.33) | LRRK2CHEK1VNN1 | |
| SCHEMBL185954 | 0.75 | DHODH (0.38) | DHODHKCNQ3KCNQ2 | |
| SCHEMBL201030 | 0.74 | LRRK2 (0.45) | LRRK2DHODHMAOB | |
| SCHEMBL2806482 | 0.74 | RAB9A (0.44) | DHODHKCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL2526330 | 0.71 | HSD11B1 (0.40) | POLBVNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | LRRK2 2304/4885DHODH 2925/4885MAOB 1822/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | LRRK2 2304/4885DHODH 2925/4885MAOB 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.